An interactive journey through the human genome to understand what we know — and what we don't — about the genetic basis of attention-deficit/hyperactivity disorder.
The whole journey of this page, summarized in steps. ADHD does not arise from a single gene, but from the sum of many influences.
Before diving into the genetics, it helps to understand the condition these genes help explain.
ADHD (attention-deficit/hyperactivity disorder) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity and impulsivity that interfere with daily life. It is not a failure of willpower or character: it reflects real differences in how certain brain circuits develop and communicate. It is one of the most heritable neurodevelopmental conditions, and every person experiences it differently.
ADHD has been described clinically for more than a century — as early as the start of the 20th century, children with marked difficulties of attention and self-control were being documented. For decades, candidate genes of the dopaminergic system were studied, but genome-scale confirmation arrived in 2019, when Demontis et al. identified the first genome-wide significant loci. It is not a recently "invented" condition: what is new is understanding its biological basis.
Symptoms are grouped into presentations (combined, predominantly inattentive, or predominantly hyperactive-impulsive) and vary widely from one person to another:
Difficulty sustaining attention, distractibility, forgetfulness, and problems with organization and following tasks through to the end. It is the core dimension of the inattentive presentation.
Restlessness, a need to move, difficulty staying still or engaging in quiet activities. It tends to be most visible in childhood and to ease with age.
Acting without thinking, interrupting, difficulty waiting one's turn or regulating responses. Together with hyperactivity it defines the hyperactive-impulsive presentation; together with inattention, the combined one.
A person may have mainly inattention, mainly hyperactivity-impulsivity, or both (combined). The profile can change over the course of life.
In girls, inattention often predominates — less conspicuous than hyperactivity — so it is frequently recognized later or goes unnoticed.
ADHD does not always "go away" with age: in many people it continues into adulthood, although outward hyperactivity tends to give way to inner restlessness and executive difficulties.
The traits usually appear in childhood and accompany the person along their path, with forms of expression that change with age.
A lot of activity and impulsivity can be normal; ADHD traits stand out for their intensity and persistence.
The demands of attention and organization make the difficulties more visible; this is often when it is diagnosed. School support is key.
Outward hyperactivity tends to decrease; inattention, impulsivity and planning challenges persist.
In many people it continues, with inner restlessness and executive difficulties. Recognition and support remain helpful.
ADHD has treatments with good evidence. The approach usually combines medication, behavioral intervention and environmental supports, tailored to each person.
Stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine) act on dopamine and noradrenaline. They are among the most effective treatments in psychiatry, always with professional follow-up.
Behavioral strategies, skills training, organization and psychoeducation for the person and their family. Especially important in childhood.
Reasonable accommodations at school or work (extra time, structure, reminders) that help the person realize their potential.
Educational content with a scientific basis (twin studies of heritability; reviews by Faraone et al.; first GWAS loci, Demontis et al. 2019). It does not replace assessment by a healthcare professional. ADHD is a form of neurological diversity that deserves understanding and support, not stigma.
DNA (deoxyribonucleic acid) is the molecule that stores the genetic instructions of every living thing. It is made up of approximately 3 billion base pairs in the human genome.
Four chemical bases — Adenine (A), Thymine (T), Cytosine (C) and Guanine (G) — are organized into a double helix. Small variations in this sequence influence how the brain develops and functions, and susceptibility to conditions such as ADHD.
Twin studies place the heritability of ADHD at around 74%, one of the highest among psychiatric disorders. But there is no single "ADHD gene".
ADHD is highly polygenic: thousands of common small-effect variants, together with rare variants and CNVs, combine to increase susceptibility. In 2019 the first 12 genome-wide significant loci were identified; today more than 27 are known.
There is no "ADHD gene". Susceptibility arises from many common variants, each with a tiny effect, that add up. Move the control to see how, as risk variants accumulate, predisposition gradually increases. It is a continuum across the population, not a yes/no.
Many ADHD genes converge on dopamine and noradrenaline signaling in the prefrontal-striatal circuit, key for attention and self-control. It is also where the medications act. Compare balanced signaling with a subtle alteration of tone.
Each chromosome harbors genes associated with ADHD. Click on one to see its regions, its evidence and the genes involved.
Search and filter among the genes with the strongest evidence. Click any card to see its function, variants and reference studies.
ADHD genes do not act in isolation: they converge on neurotransmission systems and on neurodevelopment. Hover over a node to identify it; click to see the detail.
Milestones that transformed our understanding of the genetics of ADHD, from the first candidate genes to the large GWAS studies.
The genes associated with ADHD converge on neurotransmission systems and on neurodevelopmental pathways that regulate attention and impulse control.
Genetic research on ADHD has advanced enormously over the past three decades. We know that:
The most important thing: genetics describes predisposition, not destiny. Every person with ADHD is unique, and genetic knowledge should serve to understand and support, never to label or limit.
ADHD is largely genetic and neurobiological. It is worth dismantling common and harmful myths:
The environment can influence how symptoms are expressed and the person's wellbeing, but it does not "create" ADHD. Blaming families or the person has no scientific basis and makes support harder.
The genetics of ADHD is advancing fast. These are the directions redefining the field.
Studies with ever larger samples and more varied populations will allow new loci to be found and a better understanding of the polygenic architecture of ADHD.
Polygenic risk scores summarize thousands of variants into a single figure. Their utility is being investigated — cautiously — without ever replacing clinical assessment.
Identifying genetic subtypes and the risk shared with autism, depression or other conditions to explain why ADHD is so heterogeneous.
Pharmacogenetics aims to anticipate which treatment works best for each person, reducing trial and error and improving outcomes.
Research is advancing rapidly and some of these results are preliminary: the figures and conclusions may be refined as studies grow.
The questions that come up most when talking about the genetics of ADHD, answered with rigor and respect.
Milestones and scientific sources on which this page is based.
An educational synthesis page; it is not a primary clinical source. For decisions about diagnosis or treatment, consult qualified healthcare professionals.
Six questions to check what you take away. It grades itself: tap an answer and you'll instantly see whether you got it right, with the explanation.